X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22) 22
humans (21) 21
oncology (17) 17
sarcoma (11) 11
antineoplastic agents - therapeutic use (9) 9
chemotherapy (9) 9
open-label (8) 8
pharmacology & pharmacy (8) 8
immunotherapy (7) 7
melanoma (7) 7
melanoma - drug therapy (7) 7
metastasis (6) 6
research (6) 6
sarcoma - drug therapy (6) 6
vemurafenib (6) 6
animals (5) 5
antineoplastic agents - adverse effects (5) 5
antineoplastic agents - pharmacology (5) 5
care and treatment (5) 5
clinical trials (5) 5
female (5) 5
ipilimumab (5) 5
mutation (5) 5
phase-ii (5) 5
sarcoma - pathology (5) 5
treatment outcome (5) 5
adult (4) 4
braf (4) 4
cancer (4) 4
dabrafenib (4) 4
drug therapy (4) 4
european organization (4) 4
medicine & public health (4) 4
mek (4) 4
metastatic melanoma (4) 4
middle aged (4) 4
multicenter (4) 4
pazopanib (4) 4
pembrolizumab (4) 4
protein kinase inhibitors - therapeutic use (4) 4
safety (4) 4
skin neoplasms - drug therapy (4) 4
solid tumors (4) 4
tumors (4) 4
aged (3) 3
analysis (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
b-raf (3) 3
clinical trials as topic (3) 3
combination (3) 3
development and progression (3) 3
disease progression (3) 3
docetaxel (3) 3
double-blind (3) 3
expression (3) 3
gemcitabine (3) 3
health aspects (3) 3
immunology (3) 3
immunotherapy - methods (3) 3
indoles - therapeutic use (3) 3
leiomyosarcoma (3) 3
male (3) 3
mapk (3) 3
medicine (3) 3
molecular targeted therapy (3) 3
neoplasm metastasis (3) 3
neoplasms - drug therapy (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
nivolumab (3) 3
prognosis (3) 3
programmed cell death 1 receptor - antagonists & inhibitors (3) 3
proto-oncogene proteins b-raf - antagonists & inhibitors (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
research design (3) 3
sulfonamides - therapeutic use (3) 3
t-cells (3) 3
trametinib (3) 3
trial (3) 3
1st-line (2) 2
activated protein-kinase (2) 2
angiogenesis (2) 2
angiogenesis inhibitors (2) 2
angiogènesi (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - pharmacology (2) 2
antibody (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - pharmacology (2) 2
antitumor-activity (2) 2
bevacizumab (2) 2
biomedicine, general (2) 2
bone neoplasms - genetics (2) 2
bone neoplasms - pathology (2) 2
cancer research (2) 2
cancer therapies (2) 2
caveolin 1 - genetics (2) 2
caveolin 1 - metabolism (2) 2
caveolin-1 (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 08/2013, Volume 8, Issue 8, p. e71449
Angiogenesis is the result of the combined activity of the tumor microenvironment and signaling molecules. The angiogenic switch is represented as an imbalance... 
TARGET | EPHA2 RECEPTOR | ACTIVATION | INVASION | TYROSINE KINASE | EWS/FLI-1 | MULTIDISCIPLINARY SCIENCES | EPHRINS | TUMOR | EXPRESSION | FAMILY | Humans | Receptor, EphA2 - metabolism | Sarcoma, Ewing - pathology | Bone Neoplasms - pathology | Cell Movement - genetics | Bone Neoplasms - metabolism | Heterografts | Female | Transcription, Genetic | Tumor Burden - genetics | Bone Neoplasms - genetics | Proto-Oncogene Proteins c-akt - metabolism | Disease Models, Animal | Sarcoma, Ewing - metabolism | Signal Transduction | Endothelial Cells - metabolism | Fibroblast Growth Factor 2 - biosynthesis | Gene Silencing | Caveolin 1 - genetics | Mice, Knockout | Protein Transport | Caveolin 1 - metabolism | Animals | Fibroblast Growth Factor 2 - genetics | Receptor, EphA2 - genetics | Cell Line, Tumor | Protein Binding | Neovascularization, Pathologic - genetics | Mice | Neovascularization, Pathologic - metabolism | Sarcoma, Ewing - genetics | Tyrosine | Development and progression | Fibroblast growth factors | Sarcoma | Phosphotransferases | Endothelium | Caveolin-1 | Laboratories | AKT protein | Biology | Metastasis | Kinases | Inactivation | Ewing's sarcoma | Cell adhesion & migration | Proteins | Angiogenesis | Signal transduction | Rodents | Fibroblasts | Protein-tyrosine kinase receptors | Nutrients | Children | Localization | Growth factors | Protein-tyrosine kinase | EphA2 protein | Fibroblast growth factor 2 | Ephrins | Young adults | Deactivation | Caveolin | Gene expression | Endothelial cells | Signaling | Neural networks | Ligands | Adults | Solid tumors | Prostate cancer | Cell migration | Tumors | Sarcoma d'Ewing | Neovascularization | Angiogènesi | Endoteli
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2018, Volume 19, Issue 10, pp. 1263 - 1264
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. TPS2648 - TPS2648
Journal Article
Future Oncology, ISSN 1479-6694, 02/2015, Volume 11, Issue 4, pp. 579 - 589
Vemurafenib was the first selective BRAF inhibitor licensed in cancer. It is indicated for the treatment of patients affected by advanced melanoma with BRAF... 
chemistry | MEK | pharmacodynamics | ipilimumab | pharmacokinetics | vemurafenib | melanoma | BRAF | MAPK | dabrafenib | BLADDER-CARCINOMA ONCOGENE | MULTICENTER | MUTATION-POSITIVE MELANOMA | KINASE | FOLLOW-UP | OPEN-LABEL | DACARBAZINE | ONCOLOGY | B-RAF | TRANSFORMING GENES | INHIBITORS
Journal Article
The Oncologist, ISSN 1083-7159, 12/2018, Volume 23, Issue 12, pp. 1407 - e136
Lessons Learned Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is... 
MULTICENTER | CISPLATIN | ONCOLOGY | SAFETY | BEVACIZUMAB | PD-1 BLOCKADE | VEGF | PATIENTS PTS | COMBINATION | EXPRESSION | GEMCITABINE | Clinical Trial Results
Journal Article
CANCER IMMUNOLOGY IMMUNOTHERAPY, ISSN 0340-7004, 06/2016, Volume 65, Issue 6, pp. 769 - 770
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00262-016-1845-2 
ONCOLOGY | IMMUNOLOGY | Antibodies, Monoclonal - therapeutic use | Insulins | Humans | Diabetes Mellitus - drug therapy | Insulin | Diabetes therapy | Index Medicus
Journal Article
Journal Article
Journal Article
Targeted Oncology, ISSN 1776-2596, 4/2017, Volume 12, Issue 2, pp. 125 - 138
Journal Article
Sarcoma, ISSN 1357-714X, 2012, Volume 2012, pp. 626094 - 13
Sarcomas are a heterogeneous group of mesenchymal malignancies that very often lead to death. Nowadays, chemotherapy is the only available treatment for most... 
Review
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 18, pp. 2785 - 2791
Journal Article